Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11336172 | 0.81 | SMN1; SMN2 (0.51) | MAPTPKMALDH1A1NPSR1SMN1; SMN2 | |
| SCHEMBL2905551 | 0.81 | SMN1; SMN2 (0.51) | MAPTPKMALDH1A1NPSR1SMN1; SMN2 | |
| SCHEMBL5350233 | 0.81 | MAPT (0.49) | MAPTPKMALDH1A1NPSR1SMN1; SMN2 | |
| SCHEMBL2899745 | 0.73 | ALDH1A1 (0.47) | MAPTPKMALDH1A1NPSR1SMN1; SMN2 | |
| SCHEMBL2899744 | 0.73 | ALDH1A1 (0.47) | MAPTPKMALDH1A1NPSR1SMN1; SMN2 | |
| SCHEMBL9737225 | 0.71 | MAPT (0.49) | MAPTPKMALDH1A1NPSR1SMN1; SMN2 | |
| SCHEMBL6763215 | 0.70 | MAPT (0.48) | MAPTPKMALDH1A1NPSR1SMN1; SMN2 | |
| SCHEMBL5346805 | 0.70 | MAPT (0.48) | MAPTPKMALDH1A1NPSR1SMN1; SMN2 | |
| SCHEMBL18814405 | 0.70 | MAPT (0.45) | MAPTPKMALDH1A1NPSR1SMN1; SMN2 | |
| SCHEMBL19984536 | 0.69 | ALDH1A1 (0.45) | MAPTPKMALDH1A1NPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7189728-B2 | Inhibitors of dipeptidyl peptidase IV | FERRING, BV (NL) | 2007-03-13 | — | — | US | disclosed |
| US-7144886-B2 | Dipeptidyl peptidase IV (DP-IV) inhibitors as anti-diabetic agents | FERRING B.V. (NL) | 2006-12-05 | — | — | US | disclosed |
| US-7125863-B2 | Inhibitors of dipeptidyl peptidase IV | FERRING BV (NL) | 2006-10-24 | — | — | US | disclosed |
| EP-1693365-A1 | Inhibitors of dipeptidyl peptidase IV | FERRING B.V. (NL) | 2006-08-23 | — | — | EP | disclosed |
| US-20050004205-A1 | Novel dipeptidyl peptidase iv (dp-iv) inhibitors as anti-diabetic agents | FERRING B.V. (NL) | 2005-01-06 | — | — | US | disclosed |
| EP-1280797-B1 | INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | FERRING BV (NL) | 2004-10-13 | — | — | EP | disclosed |
| EP-1450794-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV (DP-IV) INHIBITORS AS ANTI-DIABETIC AGENTS | FERRING B.V. (NL) | 2004-09-01 | — | — | EP | disclosed |
| US-20040082497-A1 | Inhibitors of dipeptidyl peptidase IV | FERRING BV (NL) | 2004-04-29 | — | — | US | disclosed |
| US-20030216450-A1 | Inhibitors of dipeptidyl peptidase IV | FERRING BV (NL) | 2003-11-20 | — | — | US | disclosed |
| WO-2003035067-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV (DP-IV) INHIBITORS AS ANTI-DIABETIC AGENTS | FERRING B.V. (NL) | 2003-05-01 | — | — | WO | disclosed |
| EP-1282600-A1 | INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | Ferring BV (NL) | 2003-02-12 | — | — | EP | disclosed |
| WO-2001081304-A1 | INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | FERRING BV (NL) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216450-A1 | Inhibitors of dipeptidyl peptidase IV | DPP4, DPP7, DPP8 | MAPT 4774/4885PKM 4649/4885ALDH1A1 1539/4885 |
| US-20040082497-A1 | Inhibitors of dipeptidyl peptidase IV | DPP4, DPP7, DPP3 | MAPT 4800/4885PKM 4030/4885ALDH1A1 568/4885 |
| US-20050004205-A1 | Novel dipeptidyl peptidase iv (dp-iv) inhibitors as anti-diabetic agents | DPP4, DPP8, DPP3 | MAPT 4833/4885PKM 3551/4885ALDH1A1 2953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.